Episode Details
Back to Episodes
Pharmaceutical Executive Daily: FDA's new Fast-Track Review
Published 7 months, 2 weeks ago
Description
In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.